Definition of Nilotinib. Meaning of Nilotinib. Synonyms of Nilotinib

Here you will find one or more explanations in English for the word Nilotinib. Also in the bottom left of the page several parts of wikipedia pages related to the word Nilotinib and, of course, Nilotinib synonyms and on the right images related to the word Nilotinib.

Definition of Nilotinib

No result for Nilotinib. Showing similar results...

Meaning of Nilotinib from wikipedia

- Nilotinib, sold under the brand name Tasigna among others, is a anti-cancer medication used to treat chronic myelogenous leukemia (CML) which has the...
- these changes resulted in the discovery of nilotinib. Nilotinib is a selective Bcr-Abl kinase inhibitor. Nilotinib is 10-30 fold more potent than imatinib...
- of imatinib. A second TK inhibitor, nilotinib, was approved by the FDA for the same indication. In 2010, nilotinib and dasatinib were also approved for...
- currently available inhibitors to treat CML are imatinib, dasatinib, nilotinib, bosutinib and ponatinib. Gastrointestinal stromal tumors (GIST) are known...
- journal). ALL and CML therapies have targeted JAK2 as well as BCR-ABL using nilotinib and ruxolitinib within murine models to downregulate downstream cytokine...
- This is a list of adverse effects of the anti-cancer drug nilotinib, sorted by frequency of occurrence. Very common (>10% incidence) adverse effects include:...
- sirolimus, alefacept, and the tyrosine kinase inhibitors, imatinib, nilotinib, and dasatinib. Experimental therapies under investigation include endothelin...
- Sorafenib (Nexavar) Sunitinib (Sutent) Dasatinib (Sprycel) Lapatinib (Tykerb) Nilotinib (Tasigna) Bosutinib (Bosulif) Ponatinib (Iclusig) Asciminib (Scemblix)...
- Approval of Dasatinib and Nilotinib for Resistant Leukemia MD Anderson researchers demonstrate the efficacy of dasatinib and nilotinib, leading to FDA approval...
- factor Kinase inhibitors: Agerafenib Axitinib Dasatinib Imatinib Masitinib Nilotinib Pazopanib Quizartinib Sorafenib Sunitinib Toceranib TGFβ See here instead...